Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. (Q37846370)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2011

Language	Label	Description	Also known as
English	Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.	scientific article published on March 2011

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

Europe PubMed Central

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

atrial fibrillation

0 references

1 reference

based on heuristic

inferred from title

Nikolaos Kakouros

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Irene Savelieva

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Antonios Kourliouros

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

A John Camm

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

1 March 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

308-328

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Increasing prevalence of atrial fibrillation and flutter in the United States

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

A multicenter risk index for atrial fibrillation after cardiac surgery

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation?

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and atrial fibrillation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Role of connexins in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Rhythm control versus rate control for atrial fibrillation and heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trial.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Atrial fibrillation and heart failure: natural history and pharmacological treatment

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Irbesartan in patients with heart failure and preserved ejection fraction

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Left ventricular hypertrophy and clinical outcomes in hypertensive patients

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Single-chamber versus dual-chamber pacing for high-grade atrioventricular block.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Current concepts in the pathogenesis of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Histological substrate of atrial biopsies in patients with lone atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Inflammation as a risk factor for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Dose-related effect of statins on atrial fibrillation after cardiac surgery

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Dose dependent effect of statins on postoperative atrial fibrillation after cardiac surgery among patients treated with beta blockers.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of preoperative statin treatment on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Statins and polyunsaturated fatty acids for treatment of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+currents and Na+current in human atrial myocytes

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Polyunsaturated fatty acid modulation of voltage-gated ion channels

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

n-3 (omega-3) polyunsaturated fatty acids prevent acute atrial electrophysiological remodeling

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Fish intake and risk of incident atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmo

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery?

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

The effect of dexamethasone on side effects after coronary revascularization procedures.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Risk of atrial fibrillation with high-dose corticosteroids

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Respiratory medications and the risk of cardiac arrhythmias

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37846370&oldid=2104983614"